US98386D3070 - ADR
XTL BIOPHARMACEUTICALS-ADR
NASDAQ:XTLB (4/18/2024, 7:00:02 PM)
2.44
-0.03 (-1.21%)
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS). hCDR1 is a peptide (short protein) that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
XTL BIOPHARMACEUTICALS-ADR
5 Badner St., P.O.Box 8241
Ramat Gan 4365603
P: 97299557080
CEO: Shlomo Shalev
Employees: 33
Website: https://www.xtlbio.com/
It's time to dive into the biggest pre-market stock movers on Tuesday as we check out all of the hottest news moving shares this morning!
expands its IP portfolio to AI Web Data The Social Proxy is a web data AI companydeveloping and powering an IP based platform for AI & BI...
Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) (
Here you can normally see the latest stock twits on XTLB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: